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Background: Histone post-translational modifications (PTMs) play an important role in the regulation of the
expression of genes, including those involved in cancer development and progression. However, our knowledge
of PTM patterns in human tumours is limited.
Methods: MS-based analyses were used to quantify global alterations of histone PTMs in colorectal cancer (CRC)
samples. Histones isolated from 12 CRCs and their corresponding normal mucosa by acidic extraction were
separated by SDS-PAGE and analysed by liquid chromatography-mass spectrometry.
Results: Among 96 modified peptides, 41 distinct PTM sites were identified, of which 7, 13, 11, and 10 were
located within the H2A, H2B, H3, and H4 sequences, respectively, and distributed among the amino-terminal tails
and the globular domain of the four histones. Modification intensities were quantified for 33 sites, of which 4
showed significant (p-value≤ 0.05) differences between CRC tissues and healthy mucosa samples. We identified histone
H3 lysine 27 acetylation (H3K27Ac) as a modification upregulated in CRC, which had not been shown previously.
Conclusions: The present results indicate the usefulness of a bottom-up proteomic approach for the detection of
histone modifications at a global scale. The differential abundance of H3K27Ac mark in CRC, a PTM associated with
active enhancers, suggests its role in regulating genes whose expression changes in CRC.
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Colorectal cancer (CRC) is the most common cancer in
the Polish population, and the leading cause of cancer-
related morbidity and mortality [1]. Most CRCs are
sporadic, and only a small proportion is associated with
hereditary disorders with high penetration, such as
Lynch syndrome, familial adenomatous polyposis and
other polyposis syndromes mediated by rare germline
mutations in DNA mismatch-repair genes and in the
adenomatous polyposis coli (APC) gene [2].
Cancer is a multi-step process involving successive
clonal selection events. The growth advantage of dysplas-
tic cells over their normal neighbours leads to progressive
cytological and architectural derangement, and individual* Correspondence: jostrow@warman.com.pl
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article, unless otherwise stated.cancer phenotypes are the result of cell-specific, develop-
mental stage-specific, and metabolism-related changes in
gene expression that occur selectively at specific times
and are modified by epigenetic interactions [3]. Epigenetic
changes such as DNA and histone modifications, chroma-
tin remodelling and regulation by noncoding RNAs can
result in massive deregulation of gene expression during
the course of cancer development [4]. The global effects
of altered epigenetic patterns in gene regulatory sequences
have been determined by the ENCODE project [5].
Histone post-translational modifications (PTMs) in-
clude lysine acetylation, arginine and lysine methylation,
phosphorylation, proline isomerization, ubiquitination
(Ub), ADP ribosylation, arginine citrullination, SUMOy-
lation, carbonylation and biotinylation [6]. The most
common PTMs are acetylation and methylation [7].
Within the five main histone proteins, PTMs can occur
at multiple positions, although they are most frequent at
histone N-terminal tails [8]. Despite the key role ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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known about the patterns of histone PTM alterations in
human tumours [9].
Proteomic methods are largely based on the use of
mass spectrometry (MS), a highly specific, effective, and
universal technique that does not require complicated
multi-step sample preparation. One of the most promin-
ent features of MS is its sensitivity, which enables the
detection of attomolar sample concentrations with an
error of 0.01% of the total sample mass. Proteomics ana-
lyses the composition, amounts, isoforms, and post-
translational modifications of cellular proteins [10].
In the present study, we used MS-based analysis to
quantify global alterations of histone PTMs in matchedFigure 1 Diagram of workflow to determine altered histones PTMs in
sections by acidic extraction using Shechter et al. protocol [36] followed by
histone core proteins were excised next proteins were digested with trypsi
performed to identify in deep the peptides that compose the collection of sa
2D maps acquired in LC-MS runs. Maps were then used as the basis to quant
CRC and normal mucosa samples.normal and colon cancer samples. Our results showed
that histone H3 lysine 27 acetylation (H3K27Ac) is asso-
ciated with colon cancer.
Results
Histones were isolated from 12 CRC tissues and corre-
sponding normal mucosa, and equal protein amounts
were separated by SDS-PAGE and subjected to qualita-
tive LC-MS/MS and quantitative label-free LC-MS
analyses (Figure 1).
Qualitative histone protein analyses
For protein identification 10 pooled samples were ana-
lysed by LC-MS/MS for protein identification, resultingcolon carcinoma tissues. Histones were isolated from whole tissue
separation using SDS-PAGE and silver staining. The gel part containing
n and subjected to MS analyses. MS/MS runs of pooled samples were
mples. The custom peptide database was further overlaid on individual
ify and point modified peptides with differential abundance between
Karczmarski et al. Clinical Proteomics 2014, 11:24 Page 3 of 10
http://www.clinicalproteomicsjournal.com/content/11/1/24in the acquisition of 386120 fragmentation spectra. A
search against the SwissProt database using the Mascot
engine confidently identified a set of 2,647 peptides with
an estimated false discovery rate of 0.01 (Additional file 1:
Table S1). In total, 522 proteins were identified, of which
357 were represented by at least two peptides (Additional
file 1: Table S2). Among the detected peptides, 285 origi-
nated from core histone proteins, including H4, H3.1,
H3.2, H3.3 and numerous variants of H2A and H2B.
However, the unambiguous identification of the members
of the two latter families was difficult. High sequence
homology between these two families leads to the detec-
tion of multiple shared peptides, which can be attributed
to more than a single protein. As a result, it is not always
possible to identify the particular proteins present in the
samples. In the present study, the indistinguishable his-
tone H2A and H2B subtypes were grouped into six and
eight distinct clusters represented by variants accounting
for all observed peptides. The final results of core histone
protein identification are summarized in Table 1, along
with the number of detected peptides and sequence
coverage. A more detailed description of their peptide-
protein dependencies is also available in Additional file 1:
Table S3.Table 1 LC-MS/MS histone protein identification in gel slices
SwissProt ACC Name Coverage [%]
P0C0S8 Histone H2A type 1 65.89
Q96KK5 Histone H2A type 1-H 66.93
Q96QV6 Histone H2A type 1-A 66.93
Q93077 Histone H2A type 1-C 65.89
Q6FI13 Histone H2A type 2-A 67.44
Q8IUE6 Histone H2A type 2-B 50.39
Q71UI9 Histone H2A.V 50.39
P0C0S5 Histone H2A.Z 50.39
P16104 Histone H2A.x 65.49
P62807 Histone H2B type 1-C/E/F/G/I 86.40
P58876 Histone H2B type 1-D 86.40
Q93079 Histone H2B type 1-H 86.40
P06899 Histone H2B type 1-J 86.40
Q99880 Histone H2B type 1-L 80.80
P23527 Histone H2B type 1-O 86.40
Q16778 Histone H2B type 2-E 86.40
P57053 Histone H2B type F-S 86.40
O60814 Histone H2B type 1-K 86.40
P68431 Histone H3.1 80.00
Q71DI3 Histone H3.2 80.00
P84243 Histone H3.3 80.00
P62805 Histone H4 80.39
Proteins matching the same sets of peptides are indicated by bolded text. Non-histThe identification of 96 modified peptides allowed for
the characterisation of 41 distinct post-translational modi-
fication sites, of which 7, 13, 11, and 10 were located
within the sequences of H2A, H2B, H3, and H4, respect-
ively (Additional file 1: Table S4 and Figure 2). Multiple
modification variants were detected on 6 sites (14.6%),
with a maximum of four different modifications per site.
As shown in Figure 2, the sites were distributed in the
amino-terminal tails and the globular domain forming the
nucleosomal core of each of the four histones. Despite the
sequence divergence, the observed modification patterns
were generally preserved within the H2A, H2B and H3
families, with the exception of H2A.V and H2A.Z variants.
Acetylation, which was observed in 36 lysine residues,
was the most prominent of all the studied modifications.
In 31 instances, it was the only modification detected
on a given site, whereas the remaining 5 sites showed
alternative modification variants, including mono-, di-
and tri-methylation (three, four, and four sites, respec-
tively). Modifications on arginine residues were signifi-
cantly less frequent and only a single site of methylation
and deamidation was detected in the sequence of the
histone H2A. Two serine and two threonine phospho-























one proteins are not listed.
Figure 2 Amino acid sequences of core histone and their forms, indicating sites of post-translational modification. The grey block marks
the N-terminal histone tail. The alignment of protein sequences and visualization of the detected modification sites were performed using CLC
Sequence Viewer (CLC Bio).
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tome [12] databases revealed that although most of the
sites had been previously reported, in several cases our
survey provided a more comprehensive list of their pos-
sible modification. For example, lysine K43 of histone
H2B, which is a known ubiquitination site, was shown to
have an acetylated variant. A detailed summary of site-
modification combinations not covered by the two data-
bases is presented in Additional file 1: Table S4.Table 2 List of histone modifications showing differences
in abundance (p-value ≤ 0.05) between cancerous (CRC)
and normal (NC) colonic mucosa
Histone Site Modification p-value FC CRC/NC
H3 K27 Trimethyl (K) 0.004032 1.67
H3 K27 Acetyl (K) 0.012378 1.54
H2B S64 Phospho (ST) 0.016537 1.24
H3 K79 Acetyl (K) 0.044106 0.83
FC, fold change.Quantitative analysis
Peptides identified by LC-MS/MS analyses were quanti-
fied in individual samples (12 CRC tissue-healthy mu-
cosa pairs) using a label-free approach and modification
intensities were calculated for each of the detected sites
(see Methods). We obtained 45 reliable quantitative es-
timates of modification intensities on 33 sites. Using a
threshold of p ≤ 0.05, 4 sites exhibiting significant diffe-
rences in modification intensity between the two sample
groups were detected (Table 2), of which three were up-
regulated and one downregulated in cancerous samples.
Among them we identified histone H3 lysine 27 acetyl-
ation (H3K27Ac) as a modification upregulated in CRC;an example of fragmentation spectrum for H3K27Ac is
presented in Additional file 2: Figure S1.
Availability of antibodies allowed further evaluation of
the two selected PTMs of histone H3, namely H3K27Ac
and K27 trimethylation (me3). Western blotting-based
analysis of histones isolated from 12 CRC tissue samples
and paired healthy mucosa samples, followed by densito-
metric analyses, confirmed increased K27 acetylation at
H3 (fold change (FC) = 1.31, p-value = 0.0093) (Figure 3),
whereas no significant differences were observed for the
H3K27me3 marker (not shown).
MS and western blot results of H3K27Ac alteration
were also confirmed by the immunohistochemical staining
Figure 3 H3K27Ac is upregulated in colon carcinoma tissues. (A) Results of H3 and H3K27Ac immunostaining in 12 pairs of CRC tissues and
normal mucosa and graphical depiction of densitometric assessment of differences (B). Histones were isolated from whole tissue sections by
acidic extraction and equal amounts of protein were separated by SDS-PAGE, electrotransferred to PVDF membranes and immunostained with
H3 (ab1791) or H3K27Ac (ab4729) antibody. Densitometric measurements were performed using OptiQuant image analysis software. H3K27Ac
level was normalised to the signal from total H3. C, CRC- colon cancer; N, NC- normal colonic mucosa.
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embedded tissue samples; five tissue pairs were com-
mon with MS and western blot analyses (Additional file 1:
Table S5). While both normal and CRC tissue reveal-
ed pronounced positive nuclear immunoreactivity for
H3K27Ac (Figure 4 and Additional file 2: Figure S2), the
percentage of positively stained nuclei (labelling index),
calculated with the use of automated image analysis
software in the representative pictures of matched nor-
mal/CRC sample sections, revealed higher ratio of immu-
nopositive cells compared to normal counterpart (69.01%
vs. 52.66% respectively, p = 0.0052) - Table 3.
To determine whether increase in H3K27Ac mark is
associated with proliferating cells, we measured its abun-
dance in four resting and dividing CRC cell lines, namelyFigure 4 An example of an immunohistochemical analysis of represe
antibody against H3K27Ac.HCT-116, Colo205, HT29 and Caco2, using the west-
ern blot. While there were no differences in H3K27Ac
levels between quiescent and proliferating cells, variable
levels of that mark were found between the cell lines
(Additional file 2: Figure S3).
Next, we wished to determine the expression of en-
zymes controlling H3K27Ac mark. To this end, using
quantitative (q) RT-PCR, we measured the mRNA levels
of enzymes controlling H3K27Ac mark abundance, namely
CBP/p300 acetyltransferases [13,14] and HDAC1 deacety-
lase [15], on 26 CRC and 24 healthy mucosa samples col-
lected in our previous study [16]. These measurements
revealed significant downregulation of CBP, p300 and
HDAC1 transcripts in CRC (Additional file 2: Figure S4)
with a FC of 0.37, 0.34 and 0.7, respectively.ntative matched normal colonic and CRC sections with use of
Table 3 H3K27Ac labelling index in matched CRC and
corresponding normal tissue sections











#details on the samples can be found in Additional file 1: Table S5.
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Histone PTMs can affect DNA-histone interactions or
inter-nucleosomal contacts, as well as the recruitment
of non-histone proteins to chromatin via bromo,
chromo and PHD domains [17,18]. Thus, PTMs are re-
sponsible for the regulation of chromatin structure and
function, constituting the epigenetic code. Although
challenging, traditional MS-based bottom-up analyses
allow the identification and characterisation of PTMs
without prior knowledge of the modification site or type
(reviewed in [6]).
In the present study, we used a bottom-up proteomic
approach to investigate alterations in histone modifica-
tions in colon cancer samples and their normal counter-
parts. We identified 96 modified histone derived peptides,
of which 45 site-modification combinations were further
quantified, revealing 4 sites with differential abundance
between cancerous and normal mucosa. For further vali-
dation, we chose histone H3 lysine 27 acetylation because
this modification has not been previously shown to be
altered in CRC [19].
Protein immunostaining on western blots confirmed
the increased K27 acetylation at H3 (Figure 3) and im-
munohistochemical staining of paired CRC and corre-
sponding normal tissue sections revealed nuclear
localisation of acetylated H3 protein (Figure 4). Since dif-
ferent morphology of cells of epithelial type is observed in
two types of tissue, the percentage of immunoractive cells
(labelling index) was calculated in the representative pic-
tures of each sample and used for the comparison of the
two types of colorectal tissue. We found significantly
higher H3K27Ac index in CRC samples compared to nor-
mal tissue which correspond the results obtained with
both of MS and western blot.
Acetylation of lysine residues is a major histone modi-
fication involved in the regulation of chromatin struc-
ture and transcription. It neutralises the positive chargeon the lysine side chain, relaxing the chromatin struc-
ture, and it generates docking sites for bromodomain-
containing proteins [20]. The balance between the en-
zymatic activities of histone lysine acetyltransferases and
deacetylases regulates the level of histone acetylation.
Furthermore, the global level of histone acetylation de-
pends on intracellular acetyl-CoA pools [21].
Acetyltransferases consist of three families, GNAT,
MYST, and CBP/p300, which generally act promiscu-
ously on more than one lysine; however, some specificity
has been observed for these enzymes [20]. Aberrant
acetylation of histones has been linked to CRC patho-
genesis (reviewed in [19]). Studies suggest that histone
acetylation is reduced in CRC and in other tumours
[22]; however, examination of specific sites shows that
acetylation can be either up- or downregulated. For ex-
ample, Fraga et al. used EC-LC-ES/MS and western blot
analysis and showed a loss of monoacetylation at H4K16
in CRC cell lines [23]. Global hypoacetylation of H4K12
and H3K18 has been observed in undifferentiated colo-
rectal adenocarcinomas, whereas their acetylation was
increased in well-differentiated tumours [24]. Contrary
to these findings, the H3K9 hypoacetylation status was
positively correlated with tumour histological type and
low H3K9Ac was observed in well-differentiated tu-
mours [25]. To the best of our knowledge, aberrant
H3K27Ac levels in CRC have not been reported to date.
In other solid tumours, namely lung adenocarcinomas
and squamous cell carcinomas, the increase in H3K27
acetylation is more pronounced in the tumour compart-
ment than in the corresponding stroma [26].
H3K27Ac was first discovered in yeast [27] and is
present in animals and plants [28]. Recent advancements
in DNA sequencing technology have enabled the ana-
lysis of histone modification distribution patterns across
the genome. These studies have shown that among his-
tone acetylation marks [29], H3K27Ac is frequently as-
sociated with active enhancer regulatory elements [30],
and genes associated with these enhancers are expressed
at higher levels than those lacking the H3K27Ac mark
[31]. The H3K27Ac mark is established by CBP/p300
acetyltransferase [13,14] and is likely erased by RBP3/
HDAC1 [15]. Contrary to the report by Ishihama et al.
who found CBP/p300 and HDAC1 mRNAs [32] upregu-
lated in CRC, our qPCR measurements showed decreased
levels of these transcripts (Additional file 2: Figure S4).
The discrepancy could be due to the differences in the
methodologies of transcripts measurements; while Ishi-
hama et al. used both semi-quantitative endpoind RT-PCR
and in situ hybridisation [32], in this study we used qPCR
which is regarded as a gold standard for the quantification
of nucleic acids [33]. Although other reports highlighted
higher abundances of CBP/p300 and HDAC1 proteins in
CRC tissue [34,35], it must be stressed that the alterations
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tirely responsible for specific histone modification levels,
because other variables such as substrate availability and
enzyme activity may contribute to the final modification.
Conclusions
In conclusion, for the first time, we show that H3K27Ac
mark is increased in CRC. Further experiments, which
are beyond the scope of this study, such as chromatin
immunoprecipitation followed by deep sequencing (ChIP-
Seq) in colon tissues to examine the distribution of the
H3K27Ac mark, may identify enhancer regulatory sites
that differ in mark levels between normal and cancerous
samples. Such datasets combined with increased know-
ledge on genome regulatory elements and long genomic
interactions deposited in the ENCODE database [5]
could potentially lead to the identification of genes




Patients were selected as described previously [4]. The
study protocol was approved by the Cancer Center
Bioethics Committee, and all patients signed informed
consent forms before inclusion. Twelve sporadic CRC
samples and paired full-thickness normal colon frag-
ments were obtained by surgical resection through lapar-
otomy, snap frozen in liquid nitrogen within 10–30 min
of harvesting and stored at 72°C until use. To select
samples with a high content of normal and dysplastic
mucosa, several series of cryostat sections were prepared
from different parts of each specimen using a Microm
HM 505E (Zeiss, Germany). Histological evaluation of
the upper and lower sections from each cryosection col-
lection revealed a 70% median-relative content of normal
mucosa (range 40 − 90%) and 50% (20 − 90%) dysplastic
mucosa in the specimens. Clinical characteristics and
histopathology of the tissue samples used in a study is pre-
sented in Additional file 1: Table S5.
Colon adenocarcinoma cell lines
HCT-116, Colo205, HT-29 and Caco2 cell lines were
purchased from ATCC and maintained under standard
conditions in culture medium (HCT-116 and HT-29 –
McCoy’s 5A Medium; Colo205 – RPMI-1650 medium;
Caco2 – DMEM medium) supplemented with 10% FBS
(Fetal Bovine Serum). Cells were made quiescent by low-
ering FBS concentration to 0.5% FBS for 24 h prior to
harvest.
Histones extraction
Histones were isolated from whole tissue sections by
H2SO4 extraction [36] and equal amounts of sampleprotein (20 μg) were separated by standard 15% SDS-
PAGE and silver stained. Gel fragments containing H2A,
H2B, H3, and H4 bands were cut out separately for each
electrophoresis line; proteins in the gel were reduced,
alkylated, and trypsin-digested using standard protocols,
and the resulting peptides were extracted using 0.1%
TFA/2% acetonitrile (ACN).
Western blot and densitometric data analyses
For western blotting, 5 μg of each protein sample was
resolved by SDS-PAGE and electrotransferred to a PVDF
membrane. Blotted proteins were detected using the
following antibodies: H3 (ab1791, Abcam), H3K27Ac
(ab4729, Abcam), H3K27me3 (07–449, Millipore). Pro-
tein band intensities were assessed by densitometry
using OptiQuant image analysis software (Packard). Data
were normalised to the amount of total histone H3 and
expressed as fold change in CRC tissues versus control
samples. The statistical significance of histone modifica-
tions between two tissue types, as detected by western
blotting, was determined with the nonparametric Wil-
coxon signed-rank test, and p-values of ≤ 0.05 were con-
sidered significant.
Quantitative RT-PCR
Measurements of mRNA abundances were performed on
the 26 CRC and 24 healthy mucosa samples and with a q-
RT-PCR protocol described previously [16]. The se-
quences of primers used were as follow: HDAC1, forward
5′- CAATGAAGCCTCACCGAATC-3′, reverse 5′- CTC
CTCAGCATTGGCTTTGT-3′; CBP, forward 5′- GTTTC
CCCGCAAATGACTG-3′, reverse 5′- CTGCCCTCCAG
CTTGACTAA-3′; p300, forward 5′- CATGAATCCAGG
GCCTAACA-3′, reverse 5′- CGGATCATACTTGGGTC
AGG-3′.
Immunohistochemistry
Staining was performed in 4 μm formalin-fixed, paraffin-
embedded tissue sections of CRCs and matched normal
mucosa from 10 patients (Additional file 1: Table S5)
with the use of Envision Detection System (DAKO). Sec-
tions were deparaffinized with xylene and rehydrated in
a series of decreasing concentration of ethanol solutions.
Heat-induced epitope retrieval was carried out in Target
Retrieval Solution (pH 6) (DAKO) in a 96°C water bath,
for 20 minutes. After cooling retrieval solutions for
25 minutes at room temperature, the slides were treated
for 5 minutes with Blocker of Endogenous Peroxidase
(DAKO). Slides were incubated with anti-H3K27Ac
(ab4729, Abcam) (diluted 1:500) for 30 minutes at room
temperature and subsequently labeled with the Envision
Detection System (DAKO). Color reaction product was
developed with 3,3′-diaminobenzidine, tetrahydrochlo-
ride (DAB) (DAKO) as a substrate, and nuclear contrast
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tative pictures of each sample were taken at magnification
x400 and used for the automatic calculation of the per-
centage of positively stained nuclear area (labeling index).
For this purpose ImmunoRatio i.e. softwere for automated
image analysis [37] was used and the results for normal
samples and CRC sections were compared.LC-MS settings
LC-MS analysis of histone peptides was performed used
a LTQ-Orbitrap Velos mass spectrometer (Thermo Scien-
tific) coupled with a nanoAcquity (Waters Corporation)
LC system. Spectrometer parameters were as follows: po-
larity mode, positive; capillary voltage, 1.5 kV. A sample
was first applied to the nanoACQUITY UPLC Trapping
Column (Waters) using water containing 0.1% formic acid
as the mobile phase. Next, the peptide mixture was trans-
ferred to the nanoACQUITY UPLC BEH C18 Column
(Waters, 75 μm inner diameter; 250 mm long) and an
ACN gradient (5–40% over 100 min) was applied in the
presence of 0.1% formic acid with a flow rate of 250
nl/min and eluted directly to the ion source of the mass
spectrometer. Each LC run was preceded by a blank run
to avoid sample carry-over between the analyses.
Qualitative LC-MS/MS analyses were performed on
pooled samples in data-dependent acquisition mode. Up
to 5 MS/MS processes were allowed for each MS scan,
and high-energy collision dissociation (HCD) was used
for peptide fragmentation. Quantitative analyses of indi-
vidual samples were performed by using separate survey
scan LC-MS runs with a m/z measurement range of
300–2,000 and the same ACN gradient settings as those
used for the LC-MS/MS runs. The data-dependent MS-
to-MS/MS switch was disabled, and the spectrometer
resolution was set to 15,000.Qualitative MS data processing and database search
The acquired MS/MS raw data files were preprocessed
with Mascot Distiller (version 2.2.1, Matrix Science), and
the resulting peak lists were searched against the Homo
sapiens entries of the SwissProt database (version
05.10.2012, 20306 sequences) using Mascot (version
2.2.03, Matrix Science). The search parameters were as
follows: enzyme specificity: semitrypsin; maximum num-
ber of missed cleavages: 2; protein mass: unrestricted; par-
ent ions mass error tolerance: 5 ppm; fragment ions mass
error tolerance: 0.02 Da; fixed modifications: Carbamido-
methylation (C); and variable modifications: Acetyl (K)
(42.010565 Da), Methyl (K) (14.015650 Da), Dimethyl (K)
(28.031300 Da), Trimethyl (K) (42.046950 Da), Methyl (R)
(14.015650 Da), Dimethyl (R) (28.031300 Da), Deamidated
(R) (0.984016 Da), Phospho (ST) (79.966331 Da) and Oxi-
dation (M) (15.994915 Da).The statistical significance of peptide identifications
was determined using a target/decoy database search ap-
proach and a previously described procedure that pro-
vided q-value estimates for each peptide spectrum
match (PSMs) in the data set [38,39]. Only PSMs with
q-values ≤ 0.01 were regarded as confidently identified.
Additional acceptance criteria were used for assessing
confidence of modified peptides. In the first step, the
exact position of the modifications in the sequence was
established by an adopted version of the phosphoRS al-
gorithm [40]. Next, the MS/MS spectra were inspected
manually for accurate fragment ions assignment. Finally,
selected types of sites were rejected as potential experi-
mental artifacts. Those included: lysine methylations on
the C-terminus of the sequence or detected in peptides
with acidic residues (possible artifacts of methyl esterifi-
cation of the carboxylic group) and peptides with deami-
dation on the C-terminal arginine (tryptic cleavage after
a deamidated residue have been recently shown as a
highly unlikely event [41]).
Proteins represented by less than two peptides, or
identified by a subset of peptides from another protein,
were excluded from further analysis. Proteins matching
the same set of peptides were grouped together into
clusters. All the steps involved in Mascot results pro-
cessing were performed using MScan, a proprietary Java
application available at http://proteom.ibb.waw.pl/mscan.
Multiple alignment of protein sequences and visualization
of the detected post-translational modification sites were
performed using CLC Sequence Viewer (CLC Bio).
Quantitative MS data processing
Peptides identified in all LC-MS/MS runs were merged
into a common list, which was next overlaid onto 2-D
maps generated from the LC-MS profile data of individ-
ual samples. The feature extraction procedure was de-
scribed in detail in a previous study [42]. Briefly, the list
of identified peptides was used to tag the corresponding
peptide-related ion spectra based on m/z differences, de-
viations from the predicted elution times, and the match
between the theoretical and observed isotopic envelopes.
The maximum deviation accepted in m/z and the retention
time were established separately for each of the processed
LC-MS spectra to account for possible variations in mass
measurement accuracy and chromatographic separation
between runs. First, an initial search with wide tolerance
and restrictive parameters of isotopic envelope fits was per-
formed. Next, nonlinear mass and time calibration func-
tions were calculated using LOESS regression, and the
search was repeated with narrowed tolerances and relaxed
fit requirements. Finally, relative abundances of peptide
ions were determined as the heights of 2-D fits to the
most prominent peaks of the tagged isotopic envelopes.
For normalisation purposes, the calculated abundance of
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the peptides detected in the sample.
Given the normalised peptide abundances, quantitative
values (further referred to as “modification intensities”)
were calculated for distinct post-translational modifica-
tion types observed on each of the previously identified
sites. These values were computed using a procedure
that involved rescaling of the abundances of single-
modified peptides covering the site of interest to a com-
mon level, followed by computing their median value.
Statistical analysis of quantitative MS measurements
A non-parametric resampling-based test with paired t statis-
tics was used to evaluate the differences in site-modification
intensities between the two groups of samples. Modification
sites with p-values ≤ 0.05 were considered as significantly
changed.
Additional files
Additional file 1: Table S1. The list of peptides identified in MS/MS
analyses with estimated FDR = 0.01. Table S2. The list of identified
proteins together with their MS/MS-related details. SCORE - MascotScore;
PEPT# - number of peptides assigned to protein. Proteins matching to
the same sets of peptides were grouped into unique clusters and
presented as single rows of the table. Table S3. List of identified core
histone-derived peptides. Table S4. List of identified postranslational
modification sites core histone proteins. Site-modification combinations
not present in PhopshoSitePlus and/or Histome databases are marked in
red. Table S5. Clinical characteristics and histopathology of the tissue
samples used in a study.
Additional file 2: Figure S1. An example MS/MS spectrum of the
peptide K(Ac)SAPATGGVK derived from the H3 histone proteins family.
The amino acid sequence of the peptide includes the lizyne K27 residue.
The plot was generated using the ExpertSystemGui application available
at (http://www.biochem.mpg.de/mann/tools/). Figure S2.
Immunohistochemical staining of 10 matched normal and CRC tissue
sections with use of antobody against H3K27Ac. Magnifications 100X and
400X. Figure S3. H3K27Ac mark level in quiescent and proliferating CRC
cell lines. Cells cultured for 24 h with 10% or 0.5% FBS were harvested,
histones isolated by acidic extraction and then 5 μg of protein was
resolved by SDS-PAGE and electrotransferred to PVDF membrane. Blotted
proteins were assessed by Western blot analysis using the antibodies to
H3 (ab1791) or H3K27Ac (ab4729). Densitometric measurements were
performed using OptiQuant image analysis software. H3K27Ac level was
normalised to the signal from total H3 and presented of the chart.
Figure S4. Analysis of mRNA expression levels of CBP, p300 and HDAC1
in individual tissue samples of 26 adenocarcinomas (CRC) and 24 healthy
mucosa’s (NC). One microgram of total RNA was reverse-transcribed
to generate cDNA and then qPCR was performed using SYBR Green I
chemistry. Green horizontal bars indicate means and red whiskers
indicate standard deviation. Differences were analyzed using the
Mann–Whitney test.
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